VivoSeq
Other

Cisplatin

0

Pipeline Programs↗

3

Active Trials↗

4

Companies Involved↗

Cisplatin is an early-stage landscape with 0 programs across 4 companies. The most active players are Sanofi, EMD Serono Research & Development Institute, Inc., AbbVie.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

53/100

Attrition Rate

28/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

0 programs

PreclinicalEMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.

0 programs

PreclinicalAbbVie logo

AbbVie

0 programs

PreclinicalR

RaND Biosciences

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

29

clinical trials

Completed10 · 34%
Terminated8 · 28%
Unknown status7 · 24%
Recruiting2 · 7%
Suspended1 · 3%
Not yet recruiting1 · 3%

Clinical Trials

Trial Activity

29 trials

Transtympanic STS Against Cisplatin-induced SNHL: the SOUND Trial
Recruiting·TThe Netherlands Cancer Institute·Phase 3·NCT07281508·100 enrolled
Low-Dose Weekly vs High-Dose Cisplatin
Recruiting·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·N/A·NCT03649048·100 enrolled
Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)
Not yet recruiting·UUniversity of Arizona·Phase 1/2·NCT07407582·25 enrolled
Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol
Completed·WWomen's Cancer Care Associates, LLC·Phase 3·NCT02501954·48 enrolled
TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN
Completed·Sanofi logoSanofi·Phase 3·NCT00539630·86 enrolled
Phase I Combination Ixabepilone + Cisplatin
Completed·RR-Pharm·Phase 1·NCT00832117·30 enrolled
Comparison of Two Concomitant Administration of RT With Cisplatin in Standard Infusion or Fractional Infusion
Completed·GGroupe Oncologie Radiotherapie Tete et Cou·Phase 2·NCT03330249·124 enrolled
A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer
Completed·AbbVie logoAbbVie·Phase 1·NCT00878449·12 enrolled
Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Completed·PPolaris Group·Phase 2/3·NCT02709512·249 enrolled
TRACE: Tirapazamine-Radiation And Cisplatin Evaluation
Completed·Sanofi logoSanofi·Phase 3·NCT00174837·317 enrolled
Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC
Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT02585973·12 enrolled
A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC
Completed·—·Phase 3·NCT00144989·281 enrolled
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Completed·CCanBas Co. Ltd.·Phase 1/2·NCT00700336·69 enrolled
Sodium Thiosulfate Otoprotection During Salvage Cisplatin Therapy
Suspended·—·Phase 1·NCT05756660·33 enrolled
A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC
Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00882583·22 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)